Unlock stock picks and a broker-level newsfeed that powers Wall Street.
ASX Penny Stocks To Watch In November 2024

In This Article:

As the ASX200 experiences a modest rise of 0.21% to 8,135 points, sector performance varies with Utilities leading gains and Energy lagging behind. In such a diverse market landscape, identifying promising investment opportunities requires careful consideration of financial health and growth potential. Penny stocks, often associated with smaller or newer companies, still offer intriguing possibilities for investors seeking value at lower price points; when these stocks are supported by strong fundamentals, they can present an opportunity for significant returns.

Top 10 Penny Stocks In Australia

Name

Share Price

Market Cap

Financial Health Rating

Embark Early Education (ASX:EVO)

A$0.77

A$141.28M

★★★★☆☆

Austin Engineering (ASX:ANG)

A$0.52

A$322.48M

★★★★★☆

LaserBond (ASX:LBL)

A$0.62

A$72.68M

★★★★★★

MaxiPARTS (ASX:MXI)

A$1.85

A$102.34M

★★★★★★

Helloworld Travel (ASX:HLO)

A$1.81

A$291.55M

★★★★★★

Navigator Global Investments (ASX:NGI)

A$1.665

A$815.98M

★★★★★☆

Perenti (ASX:PRN)

A$1.165

A$1.08B

★★★★★★

Atlas Pearls (ASX:ATP)

A$0.135

A$58.82M

★★★★★★

Joyce (ASX:JYC)

A$4.33

A$127.72M

★★★★★★

IVE Group (ASX:IGL)

A$2.12

A$328.36M

★★★★☆☆

Click here to see the full list of 1,033 stocks from our ASX Penny Stocks screener.

We're going to check out a few of the best picks from our screener tool.

Auctus Investment Group

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Auctus Investment Group Limited, formerly Yonder and Beyond Group Limited, is a private equity and venture capital firm focusing on mid-market growth sectors, real estate, and infrastructure, with a market cap of A$43.75 million.

Operations: The firm generates revenue of A$7.70 million from its Information Technology segment.

Market Cap: A$43.75M

Auctus Investment Group has demonstrated a significant turnaround, becoming profitable this year with net income of A$2.01 million for the full year ended June 30, 2024, compared to a net loss previously. Despite this positive shift, revenue declined to A$3.77 million from A$16.14 million the prior year. The company maintains a strong balance sheet with no debt and short-term assets exceeding both short- and long-term liabilities. However, shareholder dilution occurred over the past year with shares outstanding increasing by 6.3%. The management team is experienced, averaging over six years in tenure.

ASX:AVC Financial Position Analysis as at Nov 2024
ASX:AVC Financial Position Analysis as at Nov 2024

Optiscan Imaging

Simply Wall St Financial Health Rating: ★★★★★★